Welcome to our dedicated page for ZyVersa Therapeutics SEC filings (Ticker: ZVSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ZyVersa Therapeutics, Inc. (ZVSA) SEC filings page on Stock Titan brings together the company’s regulatory disclosures, offering a structured view of how this clinical-stage biopharmaceutical company reports its activities to the U.S. Securities and Exchange Commission. ZyVersa focuses on developing first-in-class drugs for renal and inflammatory diseases, and its filings provide detailed information on financial performance, capital structure, risk factors, and pipeline progress for Cholesterol Efflux Mediator™ VAR 200 and Inflammasome ASC Inhibitor IC 100.
Key documents for ZyVersa include quarterly reports on Form 10-Q and any related Form 12b-25 (NT 10-Q) notifications, which explain delays in filing and highlight significant changes in results, such as non-cash impairment charges related to in-process research and development. These filings give insight into research and development spending, general and administrative expenses, net losses, and the company’s assessment of its liquidity and need for additional financing.
Investors can also review multiple current reports on Form 8-K that ZyVersa files to disclose material events. Recent 8-Ks describe equity purchase agreements with institutional investors, warrant exercise inducement transactions, delisting notices from The Nasdaq Stock Market, changes in executive and board positions, and the announcement of financial results. One 8-K, together with a Form 25, documents the removal of ZyVersa’s common stock from listing on Nasdaq and notes that the stock is quoted on the OTCQB Venture Market under the symbol ZVSA.
For those tracking capital markets activity, ZyVersa’s registration statement on Form S-1 outlines an offering and resale framework associated with its equity purchase agreement, including the number of shares that may be issued and the registration rights granted to the investor. The Form 25 (25-NSE) filing confirms the delisting of the company’s common stock from Nasdaq under Exchange Act Rule 12d2-2.
On Stock Titan, these filings are supplemented with AI-powered summaries that explain the core points of each document in accessible language. Users can quickly see what ZyVersa reports about its financial condition, financing arrangements, listing status, and development programs, then drill down into the full 10-Q, 8-K, S-1, NT 10-Q, or Form 25 text as needed. The page also provides convenient access to insider and governance-related disclosures that appear in 8-K items about director and officer departures or appointments.
ZyVersa Therapeutics (NASDAQ:ZVSA) has entered into a significant Equity Purchase Agreement with Williamsburg Venture Holdings. The agreement provides ZyVersa with the right to sell up to $10 million of common stock through June 24, 2027. The purchase price will be set at 94% of the lowest traded Volume-Weighted Average Price during a 3-day period after share issuance.
Key terms include a 2.5% commitment fee in additional shares, issuance limitations of 19.99% of outstanding shares without stockholder approval, and mandatory registration of shares within 120 days. The company will maintain control over the timing and amount of any sales based on market conditions and financing needs.